Allosteric Modulation: A New Approach for the Treatment of Parkinson’s Disease

The dopamine D2 receptor (D2R) is a validated target for the treatment of Parkinson’s disease. To date, drug discovery efforts have focused on targeting the D2R orthosteric binding site, which cause significant side-effects. The proposed new class of allosteric drugs will act to ‘tune up’ the activity of dopamine at the D2R.

Alteristic modulation for the treatment of Parkinson's disease

Enhanced research experience

The project will entail the candidate undertaking the chemical synthesis of novel target compounds under the supervision of Dr Ben Capuano and Professor Peter Scammells in the medicinal chemistry theme at Monash Institute Pharmaceutical Science, and perform molecular pharmacology assays to ascertain compound affinity and functional potency under the supervision of Dr Rob Lane in the drug discovery biology theme at Monash Institute Pharmaceutical Science.